NEW YORK, Nov. 10, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…